WAYS TO SUPPORT MY WORK ⬇️
💊 OVER THE COUNTER ORAL PEPTIDE SUPPLIMENTS: 
BPC-157 // Can’t Weight // TB4-FRAG // KPV 
Sign up here and use code “OTP10” to save 10% 
https://integrativepeptides.com/OTP
WHY I TRUST INTEGRATIVE PEPTIDES: 
🇺🇸 Made in the USA 
📋 CGMP Compliant (FDA oversight of their products) 
🧑‍⚕️Trusted and Sold By Doctors and Clinics all over the USA
📕 GET MY BOOK! 
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp 
https://amzn.to/4gAXrz4
SOCIALS: 
📸 : https://www.instagram.com/onthepen.official/profilecard/?igsh=dTRhY3JkYWo1bTIx 
🇨🇳: https://www.tiktok.com/@manonthemounjaro?_t=ZP-8sr5PrUuPQl&amp;_r=1 
👾: https://discord.gg/ZHeUh7WV 
📺: https://youtube.com/@ManOnTheMounjaro?feature=shared 
❌: https://x.com/manonthepen?s=21 
💻: https://www.onthepen.com

Novo Nordisk and Eli Lilly are racing to bring oral GLP-1 medications to market, but will pills like oral Wegovy (semaglutide) and orforglipron actually lower the cost of obesity treatment? In this episode of On The Pen, Dave breaks down what these pills mean for real patients, how GLP-1 access is still blocked by PBMs and high prices, and why lawsuits, compounding, and legislative reform still matter.

We cover the FDA’s handling of tirzepatide shortages, Jeff Cook’s 503B compounding proposal, and the raw truth about Rybelsus inefficiency and Wegovy pill limitations. Dave also previews his trip to Washington, DC to speak with lawmakers, industry lobbyists, and the Obesity Action Coalition (OAC) to fight for patient access.

Tags: GLP-1, Wegovy pill, oral semaglutide, orforglipron, Zepbound, tirzepatide, Ozempic pill, Rybelsus, GLP-1 lawsuit, compounding pharmacies, FDA tirzepatide, Jeff Cook Noom, obesity access, PBM reform, obesity medication, GLP-1 affordability, On The Pen

High Dose Semaglutide Incoming! How Much Will it Cost? // OTP TWD 4.22.25